• Deutsches Primatenzentrum
DPZ-Hauptseite
RSS
Twitter
YouTube
deutschEnglish
Menü mobile menu

2023

  1. Wettstein L, Immenschuh P, Weil T, Conzelmann C, Almeida-Hernández Y, Hoffmann M, Kempf A, Nehlmeier I, Lotke R, Petersen M, Stenger S, Kirchhoff F, Sauter D, Pöhlmann S, Sanchez-Garcia E, Münch J (2023): Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection. Journal of Medical Virology. doi: 10.1002/jmv.28124.
     
  2. Arora P, Kempf A, Nehlmeier I, Schulz SR, Jäck HM, Pöhlmann S, Hoffmann M (2023): Omicron sublineage BQ.1.1 resistance to monoclonal antibodies. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00733-2.
     
  3. Hoffmann M, Behrens GMN, Arora P, Kempf A, Nehlmeier I, Cossmann A, Manthey Luis, Dopfer-Jablonka A (2023): Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00792-7.
     
  4. Hofmann-Winkler H, Siregar AR, Rodriguez-Polo I, Esiyok N, Gärtner S, Behr R, Pöhlmann S, Winkler M (2023): Primate simplexviruses differ in tropism for macaque cells. Microorganisms. doi: 10.3390/microorganisms11010026.
     
  5. Arora P, Cossmann A, Schulz SR, Ramos GM, Stankov MV, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2023): Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00831-3.
     
  6. Cable J, Balachandran S, Daley-Bauer LP, Rustagi A, Antony F, Frere JJ, Strampe J, Kedzierska K, Cannon JL, McGargill MA, Weiskopf D, Mettelman RC, Niessl J, Thomas PG, Briney B, Valkenburg SA, Bloom JD, Bjorkman PJ, Iketani S, Rappazzo CG, Crooks CM, Crofts KF, Pöhlmann S, Krammer F, Sant AJ, Nabel GJ, Schultz-Cherry S (2023): Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia report. Annals of the New York Academy of Sciences. doi: 10.1111/nyas.14960.
     
  7. Hoffmann M, Arora P, Nehlmeier I, Kempf A, Cossmann A, Schulz SR, Ramos GM, Manthey LA, Jäck HM, Behrens GMN, Pöhlmann S (2023): Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5. Cellular and Molecular Immunology. doi: 10.1038/s41423-023-00988-0.
  8. Metzdorf K, Jacobsen H, Greweling-Pils MC, Hoffmann M, Lüddecke T, Miller F, Melcher L, Kempf A, Nehlmeier I, Bruder D, Widera M, Ciesek S, Pöhlmann S, Cicin-Sain L (2023): TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection. Viruses. doi: 10.3390/v15020271.
     
  9. Shilts J, Crozier TWM, Teixeira-Silva A, Gabaev I, Gerber PP, Greenwood EJD, Watson SJ, Ortmann BM, Gawden-Bone CM, Pauzaite T, Hoffmann M, Nathan JA, Pöhlmann S, Matheson NJ, Lehner PJ, Wright GJ (2023): LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein. PLoS Biology. doi: 10.1371/journal.pbio.3001959.
     
  10. Oh DQP, Grothe I, Lukaß H, Kreiter AK, Hoffmann M, Wegener D (2023): Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca mulatta). Scientific Reports. doi: 10.1038/s41598-023-30473-7.
     
  11. Reiter S, Gärtner S, Decker K, Pöhlmann S, Winkler M (2023): Development of immortalized rhesus macaque kidney cells supporting infection with a panel of viruses. PLoS One. doi: 10.1371/journal.pone.0284048.
     
  12. Nehlmeier I, Kempf A, Arora P, Cossmann A, Dopfer-Jablonka A, Stankov MV, Schulz SR, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2023): Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage. Cellular and Molecular Immunology. doi: 10.1038/s41423-023-01030-z.
     
  13. Hoffmann M, Wong LYR, Arora P, Zhang L, Rocha C, Odle A, Nehlmeier I, Kempf A, Richter A, Halwe NJ, Schön J, Ulrich L, Hoffmann D, Beer M, Drosten C, Perlman S, Pöhlmann S (2023): Omicron subvariant BA.5 efficiently infects lung cells. Nature Communications. doi: 10.1038/s41467-023-39147-4.
     
  14. Budhadev D, Hooper J, Rocha C, Nehlmeier I, Kempf A, Hoffmann M, Krüger N, Zhou D, Pöhlmann S, Guo Y (2023): Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein. JACS Au. doi: 10.1021/jacsau.3c00163.
     
  15. Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A, Valneva Phase 3 Booster Trial Group (2023): Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial. The Journal of Infection. doi: 10.1016/j.jinf.2023.06.022.
     
  16. Krüger N, Kronenberger T, Xie H, Rocha C, Pöhlmann S, Su H, Xu Y, Laufer SA, Pillaiyar T (2023): Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19. Pharmaceuticals (Basel). doi: 10.3390/ph16020190.
     
  17. Fricke T, Schlagowski S, Liu S, Yang X, Fiebig U, Kaul A, Ensser A, Hahn AS (2023): Comparison of a Genotype 1 and a Genotype 2 Macaque Foamy Virus env Gene Indicates Distinct Infectivity and Cell-Cell Fusion but Similar Tropism and Restriction of Cell Entry by Interferon-Induced Transmembrane Proteins. Viruses. doi: 10.3390/v15020262.
     
  18. Zhang L, Kempf A, Nehlmeier I, Cossmann A, Dopfer-Jablonka A, Stankov MV, Schulz SR, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2023): Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(23)00547-9.
     
  19. Hofmann-Winkler H, Siregar AR, Esiyok N, Rodriguez-Polo I, Gärtner S, Behr R, Pöhlmann S, Winkler M (2023): Primate Simplexviruses Differ in Tropism for Macaque Cells. Microorganisms. doi: 10.3390/microorganisms11010026.
     
  20. Katzmarzyk M, Clesle DC, van den Heuvel J, Hoffmann M, Garritsen H, Pöhlmann S, Jacobsen H, Cicin-Sain L (2023): Systematical assessment of the impact of single spike mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of post-vaccination sera. Frontiers in Immunology. doi: 10.3389/fimmu.2023.1288794.

 

2022

  1. Hoffmann M, Pöhlmann S (2022): Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1. Cell Research. doi: 10.1038/s41422-021-00603-9.
     
  2. Kim Y, Zheng X, Eschke K, Chaudhry MZ, Bertoglio F, Tomic A, Krmpotic A, Hoffmann M, Bar-On Y, Boehme J, Bruder D, Ebensen T, Brunotte L, Ludwig S, Messerle M, Guzman C, Mandelboim O, Hust M, Pöhlmann S, Jonijc S, Cicin-Sain L (2022): MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cellular & Molecular Immunology. doi: 10.1038/s41423-021-00814-5. Epub 2022 Jan 7.
     
  3. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M, Pöhlmann S, Liu W, Hahn BH, Beil A, Kroschel J, Jahrsdörfer B, Schrezenmeier H, Kirchhoff F, Münch J, Müller JA (2022): Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. doi: 10.1016/j.ebiom.2021.103761.
     
  4. Peter AS, Roth E, Schulz SR, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-Schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Grüner E, Peterhoff D, Ciesek S, Hoffmann M, Pöhlmann S, McKay PF, Shattock RJ, Wölfel R, Socher E, Wagner R, Eichler J, Sticht H, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler TH, Grunwald T, Überla K, Jäck HM (2022): A pair of non‐competing neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model. European Journal of Immunology. doi: 10.1002/eji.202149374. Epub 2021 Sep 13.
     
  5. Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck HM, Pöhlmann S, Hoffmann M (2022): No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Cellular & Molecular Immunology. doi: 10.1038/s41423-021-00811-8. Epub 2022 Jan 5.
     
  6. Hoffmann M, Sidarovich A, Arora P, Krüger N, Nehlmeier I, Kempf A, Graichen L, Winkler MS, Niemeyer D, Goffinet C, Drosten C, Schulz S, Jäck HM, Pöhlmann S (2022): Evidence for an ACE2-independent entry pathway that can protect from neutralization by an antibody used for COVID-19 therapy. mBio. doi: 10.1128/mbio.00364-22. Epub 2022 Apr 25.
     
  7. Arora P, Sidarovich A, Graichen L, Hörnich B, Hahn A, Hoffmann M, Pöhlmann S (2022): Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. PLoS One. doi: 10.1371/journal.pone.0265453. eCollection 2022.
     
  8. Arora P, Kempf A, Nehlmeier I, Graichen L, Winkler MS, Lier M, Schulz S, Jäck HM, Cossmann A, Stankov MV, Behrens GMN, Pöhlmann S, Hoffmann M (2022): SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell Reports. doi: 10.1016/j.celrep.2022.110754. Epub 2022 Apr 15.
     
  9. Arora P, Zhang L, Krüger N, Rocha C, Sidarovich A, Schulz S, Kempf A, Graichen L, Moldenhauer AS, Cossmann A, Dopfer-Jablonka A, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M (2022): SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell Host & Microbe. doi: 10.1016/j.chom.2022.04.017. Epub 2022 May 6.
     
  10. Arora P, Kempf A, Nehlmeier I, Graichen L, Schulz S, Cossmann A, Dopfer-Jablonka A, Winkler MS, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2022): Effificient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2. Cellular & Molecular Immunology. doi: 10.1038/s41423-022-00870-5. Epub 2022 May 17.
     
  11. Damert A (2022): SVA Retrotransposons and a Low Copy Repeat in Humans and Great Apes: A Mobile Connection. Molecular Biology & Evolution. doi: 10.1093/molbev/msac103.
     
  12. Jäger N, Hoffmann M, Pöhlmann S, Krüger N (2022): Nafamostat-mediated inhibition of SARS-CoV-2 ribosomal 2 frameshifting is insufficient to impair viral re. Comment on Munshi et al. Identifying Inhibitors of –1 Programmed Ribosomal Frameshifting in a Broad Spectrum of Coronaviruses. Viruses. doi: 10.3390/v14071526.
     
  13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, Nehlmeier I, Graichen L, Moldenhauer AS, Winkler MS, Lier M, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Pöhlmann S (2022): The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
     
  14. Arora P, Kempf A, Nehlmeier I, Schulz SR, Cossmann A, Stankov MV, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2022): Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00422-4.
     
  15. Hoffmann M, Arora P, Pöhlmann S (2022): Understanding Omicron: Transmissibility, immune evasion and antiviral intervention. Clinical & Translational Medicine. doi: 10.1002/ctm2.839.
     
  16. Chaudhry MZ, Eschke K, Hoffmann M, Grashoff M, Abassi L, Kim Y, Brunotte L, Ludwig S, Kröger A, Klawonn F, Pöhlmann S, Cicin-Sain L (2022): Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases. Journal of Virology. doi: 10.1128/jvi.02186-21. Epub 2022 Jan 12.
     
  17. Hoffmann M, Zhang L, Pöhlmann S (2022): Omicron: Master of immune evasion maintains robust ACE2 binding. Signal transduction & targeted therapy. doi: 10.1038/s41392-022-00965-5.
     
  18. Jäger N, Ayyub SA, Korniy N, Peske F, Hoffmann M, Rodnina MV, Pöhlmann S (2022): Mutagenic Analysis of the HIV Restriction Factor Shiftless. Viruses. doi: 10.3390/v14071454.
     
  19. Wettstein L, Knaff PM, Kersten C, Müller P, Weil T, Conzelmann C, Müller JA, Brückner M, Hoffmann M, Pöhlmann S, Schirmeister T, Landfester K, Münch J, Mailänder V (2022): Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture. Communications Biology. doi: 10.1038/s42003-022-03613-4.
     
  20. Khanna K, Raymond WW, Jin J, Charbit AR, Gittin I, Tang M, Werts AD, Barrett EG, Cox JM, Birch SM, Martinelli R, Sperber HS, Franz S, Duff T, Hoffmann M, Healy AM, Oscarson S, Pöhlmann S, Pillai SK, Simmons G, Fahy JV (2022): Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. American Journal of Physiology. Lung cellular & Molecular Physiology. doi: 10.1152/ajplung.00136.2022.
     
  21. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, Cossmann A, Manger B, Baier E, Tampe B, Moerer O, Dickel S, Dopfer-Jablonka A, Jäck HM, Behrens GMN, Winkler MS, Pöhlmann S, Hoffmann M (2022): Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00224-9.
     
  22. Arora P, Nehlmeier I, Kempf A, Cossmann A, Schulz SR, Dopfer-Jablonka A, Baier E, Tampe B, Moerer O, Dickel S, Winkler MS, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2022): Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00591-6.
     
  23. Singh P, Mukherji S, Basak S, Hoffmann M, Das DK (2022): Dynamic Ca 2+ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. Cell Reports. doi: 10.1016/j.celrep.2022.110694.
     
  24. Behrens GMN, Barros-Martins J, Cossmann A, Ramos GM, Stankov MV, Odak I, Dopfer-Jablonka A, Hetzel L, Köhler M, Patzer G, Binz C, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Krähling V, Bernhardt G, Hoffmann M, Pöhlmann S, Krey T, Bosnjak B, Hammerschmidt SI, Förster R (2022): BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. Nature Communications. doi: 10.1038/s41467-022-32527-2.
     
  25. Schreiber A, Viemann D, Schöning J, Schloer S, Zambrano AM, Brunotte L, Faist A, Schöfbänker M, Hrincius E, Hoffmann H, Hoffmann M, Pöhlmann S, Rescher U, Planz O, Ludwig S (2022): The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. Cellular & Molecular Life Sciences: CMLS. doi: 10.1007/s00018-021-04085-1.
     
  26. Urlaub A, Wolfsdorff N, Hoffmann JE, Dorok S, Hoffmann M, Anft M, Pieris N, Günther P, Schaaf B, Cassens U, Bröde P, Claus M, Picard LK, Wingert S, Backes S, Durak D, Babel N, Pöhlmann S, Renken F, Raunser S, Watzl C (2022): Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination. European Journal of Immunology. doi: 10.1002/eji.202149758.
     
  27. Zarei O, Kleine-Weber H, Hoffmann M, Hamzeh-Mivehroud M (2022): Development and Evaluation of Peptidomimetic Compounds against SARS-CoV-2 Spike Protein: An in silico and in vitro Study. Molecular Informatics. doi: 10.1002/minf.202100231.
     
  28. Seidel A, Zanoni M, Groß R, Krnavek D, Erdemci-Evin S, von Maltitz P, Albers DPJ, Conzelmann C, Liu S, Weil T, Mayer B, Hoffmann M, Pöhlmann S, Beil A, Kroschel J, Kirchhoff F, Münch J, Müller JA (2022): BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Frontiers in Immunology. doi: 10.3389/fimmu.2022.882918.
     
  29. Sidarovich A, Krüger N, Rocha C, Graichen L, Kempf A, Nehlmeier I, Lier M, Cossmann A, Stankov MV, Schulz SR, Behrens GMN, Jäck HM, Pöhlmann S, Hoffmann M (2022): Host cell entry and neutralization sensitivity of SARS-CoV-2 lineages B.1.620 and R.1. Viruses. doi: 10.3390/v14112475.
     
  30. Arora P, Zhang L, Rocha C, Graichen L, Nehlmeier I, Kempf A, Cossmann A, Ramos GM, Baier E, Tampe B, Moerer O, Dickel S, Winkler MS, Behrens GMN, Pöhlmann S, Hoffmann M (2022): The SARS-CoV-2 Delta-Omicron recombinant variant (XD) exhibits immune escape properties similar to the Omicron (BA.1) variant. International Journal of Molecular Sciences. doi: 10.3390/ijms232214057.
     
  31. Siregar AR, Gärtner S, Götting J, Stegen P, Kaul A, Schulz TF, Pöhlmann S, Winkler M (2022): A Recombinant System and Reporter Viruses for Papiine Alphaherpesvirus 2. Viruses. doi: 10.3390/v14010091.
     
  32. Ahsendorf HP, Diesterbeck US, Hotop SK, Winkler M, Brönstrup M, Czerny CP (2022): Characterisation of an Anti-Vaccinia Virus F13 Single Chain Fragment Variable from a Human Anti-Vaccinia Virus-Specific Recombinant Immunoglobulin Library. Viruses. doi: 10.3390/v14020197.
     
  33. Arora P, Zhang L, Nehlmeier I, Kempf A, Cossmann A, Dopfer-Jablonka A, Schulz SR, Jäck HM, Behrens GMN, Pöhlmann S, Hoffmann M (2022): The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages. The Lancet. Infectious Diseases. doi: 10.1016/S1473-3099(22)00693-4.
     
  34. Schlör A, Hirschberg S, Amor GB, Meister TL, Arora P, Pöhlmann S, Hoffmann M, Pfaender S, Eddin OK, Kamhieh-Milz J, Hanack K (2022): SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications. Frontiers in Immunology. doi: 10.3389/fimmu.2022.930975.
     
  35. Runft S, Färber I, Krüger J, Krüger N, Amando F, Rocha C, Pöhlmann S, Burigk L, Leitzen E, Ciurkiewicz M, Braun A, Schneider D, Baumgärtner L, Freisleben B, Baumgärtner W (2022): Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review. Veterinary Pathology. doi: 10.1177/03009858211073678.
     
  36. Pillaiyar T, Flury P, Krüger N, Su H, Schäkel L, Da Silva EB, Eppler O, Kronenberger T, Nie T, Luedtke S, Rocha C, Sylvester K, Petry MRI, McKerrow JH, Poso A, Pöhlmann S, Gütschow M, O'Donoghue AJ, Xu Y, Müller CE, Laufer SA (2022): Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination. Journal of Medicinal Chemistry. doi: 10.1021/acs.jmedchem.2c00636.
     
  37. Färber I, Krüger J, Rocha C, Armando F, von Köckritz-Blickwede M, Pöhlmann S, Braun A, Baumgärtner W, Runft S, Krüger N (2022): Investigations on SARS-CoV-2 Susceptibility of Domestic and Wild Animals Using Primary Cell Culture Models Derived from the Upper and Lower Respiratory Tract. Viruses. doi: 10.3390/v14040828.
     
  38. Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M, Pöhlmann S, Gale M, Aittokallio T, Schiffer JT, White JM, Polyak SJ (2022): Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiology Spectrum. doi: 10.1128/spectrum.03331-22.
     
  39. Jacobsen H, Strengert M, Maaß H, Alberto M, Durand Y, Katzmarzyk M, Kessel B, Harries M, Rand U, Abassi L, Kim Y, Lüddecke T, Metzdorf K, Hernandez P, Ortmann J, Heise JK, Castell S, Gornyk D, Glöckner S, Melhorn V, Kemmling Y, Lange B, Dulovic A, Marsall P, Häring J, Junker D, Schneiderhan-Marra N, Hoffmann M, Pöhlmann S, Krause G, Cicin-Sain L (2022): Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. Scientific Reports. doi: 10.1038/s41598-022-22552-y.
     
  40. Schulz SR, Hoffmann M, Roth E, Pracht K, Burnett DL, Mazigi O, Schuh W, Manger B, Mielenz D, Goodnow CC, Christ D, Pöhlmann S, Jäck HM (2022): Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies. European Journal of Immunology. doi: 10.1002/eji.202249841.
     
  41. Behrens GMN, Cossmann A, Hoffmann M (2022): Omicron spike protein: a clue for viral entry and immune evasion. Signal transduction and targeted therapy. doi: 10.1038/s41392-022-01193-7.
     
  42. Hasan MZ, Höltermann C, Petersen B, Schrod A, Mätz-Rensing K, Kaul A, Salinas G, Dressel R, Walter L (2022): Detailed phenotypic and functional characterization of CMV-associated adaptive NK. Frontiers in Immunology. doi: 10.3389/fimmu.2022.1028788.
     
  43. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, Adams C, Carpinteiro E, Gulbins A, Keitsch S, Sehl C, Soddemann M, Wilker B, Kamler M, Bertsch T, Lang KS, Patel S, Wilson GC, Walter S, Hengel H, Pöhlmann S, Lang PA, Kornhuber J, Becker KA, Ahmad SA, Fassbender K, Gulbins E (2022): Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell reports. Medicine. doi: 10.1016/j.xcrm.2020.100142.

2021

  1. Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S (2021): Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine - The Lancet. 65:103255. doi:10.1016/j.ebiom.2021.103255.
     
  2. Hörnich F, Großkopf A, Schlagowski S, Tenbusch M, Kleine-Weber H, Neipel F, Stahl-Hennig C, Hahn A (2021): SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation. Journal of Virology. 95(9):e00002-21. doi: 10.1128/JVI.00002-21.
     
  3. Laporte M, Raeymaekers V, Van Berwaer R, Vandeput J, Marchand-Casas I, Thibaut H-J, Van Looveren D, Martens K, Hoffmann M, Maes P, Pöhlmann S, Naesens L, Stevaert A (2021): The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. Plos Pathogens.17(4):e1009500. doi: 10.1371/journal.ppat.1009500.
     
  4. Henss L, Scholz T, von Rhein C, Wieters I, Borgans F, Eberhardt FJ, Zacharowski K, Ciesek S, Rohde G, Vehreschild M, Stephan C, Wolf T, Hofmann-Winkler H, Scheiblauer H, Schnierle B (2021): Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases. 223(1):56-61. doi: 10.1093/infdis/jiaa680.  
     
  5. Bosnjak B, Stein S, Willenzon S, Cordes A K, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey C, Gödecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoeper M M, Behrens G M N, Pöhlmann S, Blasczyk R, Schulz T F, Förster R (2021): Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cellular & Molecular Immunology. 18(4):936-944. doi: 10.1038/s41423-020-00573-9.
     
  6. Hempel T, Elez K, Krüger N, Raich L, Shrimp J H, Danov O, Jonigk D, Braun A, Shen M, Hall M D, Pöhlmann S, Hoffmann M, Noe F (2021): Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chemical Science. 12(38):12600-12609. doi: 10.1039/d1sc01494c.
     
  7. Lapuente D, Maier C, Irrgang P, Hübner J, Peter A S, Hoffmann M, Ensser A, Ziegler K, Winkler T H, Birkholz T, Kremer A E, Steininger P, Korn K, Neipel F, Überla K, Tenbusch M (2021): Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2 . European Journal of Clinical Microbiology & Infectious Diseases. 40(4):751-759. doi: 10.1007/s10096-020-04072-7.
     
  8. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, Adams C, Carpinteiro E, Gulbins A, Keitsch S, Sehl C, Soddemann M, Wilker B, Kamler M, Bertsch T, Lang KS, Patel S, Wilson GC, Walter S, Hengel H, Pöhlmann S, Lang PA, Kornhuber J, Becker KA, Ahmad SA, Fassbender K, Gulbins E (2021): Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell reports Medicine. 1(8):100142. doi: 10.1016/j.xcrm.2020.100142.
     
  9. Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, Fricke T, Grundmann J, Harnisch L-O, Heise D, Kernchen A, Pressler M, Stephani C, Tampe B, Kaul A, Gärtner S, Kramer S, Pöhlmann S, Winkler M S (2021): Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. Critical care explorations. 2(11):e0284. doi: 10.1097/CCE.0000000000000284.
     
  10. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, Graichen L, Hofmann-Winkler H, Kempf A, Winkler MS, Schulz S, Jäck HM, Jahrsdörfer B, Schrezenmeier H, Müller M, Kleger A, Münch J, Pöhlmann S (2021): SARS-CoV-2 variants B.1.351 and P.1
    escape from neutralizing antibodies. Cell. 184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036.
     
  11. Hoffmann M, Zhang L, Krüger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, Kempf A, Nessler S, Riggert J, Winkler M S, Schulz S, Jäck H-M, Pöhlmann S (2021): SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports. 35(3):109017. doi: 10.1016/j.celrep.2021.109017.
     
  12. Hoffmann M, Jin Y, Pöhlmann S (2021): Dalbavancin: novel candidate for COVID-19 treatment. Cell Research. 31(3):243-244. doi: 10.1038/s41422-020-00459-5.
     
  13. Hayn M, Blötz A, Rodriguez A, Vidal S, Preising N, Ständker L, Wiese S, Stürzel C M, Harms M, Gross R, Jung C, Kiene M, Jacob T, Pöhlmann S, Forssmann W-G, Münch J, Sparrer K, Seuwen K, Hahn B H, Kirchhoff F (2021): Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling. Proceedings of the National Academy of Scienes of the United States of America. 118(3):e2023776118. doi: 10.1073/pnas.2023776118.
     
  14. Ritzmann F, Chitirala P, Krüger N, Hoffmann M, Zuo W, Lammert F, Smola S, Tov N, Alagem N, Lepper P M, Pöhlmann S, Beisswenger C, Herr C, Bals R,  (2021): Therapeutic Application of alpha-1-antitrypsin in COVID-19. American Journal of Respiratory and Critical Care Medicine. 204(2):224-227. doi: 10.1164/rccm.202104-0833LE.
     
  15. Arora P, Pöhlmann S, Hoffmann M (2021): Mutation D614G increases SARS-CoV-2 transmission. Signal Transduction and Targeted Therapy. 6(1):101. doi: 10.1038/s41392-021-00502-w.
     
  16. Hein M D, Arora P, Marichal-Gallardo P, Winkler M, Genzel Y, Pöhlmann S, Schughart K, Kupke S Y, Reichl U (2021): Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles. BMC Biology. 19(1):91. doi: 10.1186/s12915-021-01020-5.
     
  17. Wettstein L, Weil T, Conzelmann C, Müller JA, Groß R, Hirschenberger M, Seidel A, Klute S, Zech F, Prelli Bozzo C, Preising N, Fois G, Lochbaum R, Knaff PM, Mailänder V, Ständker L, Thal DR, Schumann C, Stenger S, Kleger A, Lochnit G, Mayer B, Ruiz-Blanco YB, Hoffmann M, Sparrer KMJ, Pöhlmann S, Sanchez-Garcia E, Kirchhoff F, Frick M, Münch J. (2021): Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection. Nature Communications.12(1):1726. doi: 10.1038/s41467-021-21972-0.
     
  18. Imre G, Krähling V, Eichler M, Trautmann S, Ferreiros N, Aman M J, Kashanchi F, Rajalingam K, Pöhlmann S, Becker S, Meyer zu Heringdorf D, Pfleilschifter J (2021): The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience. 24(4):102266. doi: 10.1016/j.isci.2021.102266.
     
  19. Stankov M, Cossmann A, Bonifacius A, Dopfer-Jablonka A, Ramos G, Gödecke N, Zychlinsky Scharff A, Happle C, Boeck A-L, Tran A, Pink I, Hoeper M M, Blasczyk R, Winkler M S, Nehlmeier I, Kempf A, Hofmann-Winkler H, Hoffmann M, Eiz-Vesper B, Pöhlmann S, Behrens G M N (2021): Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination. Clinical Infectious Diseases. 73(11):2000-2008. doi: 10.1093/cid/ciab555.
     
  20. Tampe D, Hakroush S, Bösherz M-S, Franz J, Hofmann-Winkler H, Pöhlmann S, Kluge S, Moerer O, Stadelmann C, Ströbel P, Winkler M S, Tampe B (2021): Urinary Levels of SARS-CoV-2 Nucleocapsid Protein Associate With Risk of AKI and COVID-19 Severity: A Single-Center Observational Study. Frontiers in Medicine. 8:644715. doi: 10.3389/fmed.2021.644715.
     
  21. Carpinteiro A, Gripp B, Hoffmann M, Pöhlmann S, Hoertel N, Edwards M J, Kamler M, Kornhuber J, Becker K A, Gulbins E (2021): Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. Journal of Biological Chemistry. 296:100701. doi: 10.1016/j.jbc.2021.100701.
     
  22. Mahoney M, Damalanka VC, Tartell MA, Chung DH, Lourenço AL, Pwee D, Mayer Bridwell AE, Hoffmann M, Voss J, Karmakar P, Azouz NP, Klingler AM, Rothlauf PW, Thompson CE, Lee M, Klampfer L, Stallings CL, Rothenberg ME, Pöhlmann S, Whelan SPJ, O'Donoghue AJ, Craik CS, Janetka JW (2021): A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the National Academy of Sciences of the United States of America. 118(43):e2108728118. doi: 10.1073/pnas.2108728118.
     
  23. Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler M S, Schulz S, Jäck H-M, Stankov M, Behrens G M N, Pöhlmann S, Hoffmann M (2021): Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cellular & Molecular Immunology. 18(11):2557-2559. doi: 10.1038/s41423-021-00772-y.
     
  24. Krüger N, Rocha C, Runft S, Krüger J, Färber I, Armando F, Leitzen E, Brogden G, Gerold G, Pöhlmann S, Hoffmann M, Baumgärtner W (2021): The upper respiratory tract of felids is highly susceptible to SARS-CoV-2 infection. International Journal of Molecular Sciences. 22(19):10636. doi: 10.3390/ijms221910636.
     
  25. Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, Moldenhauer A-S, Winkler M S, Schulz S, Jäck H-M, Stankov M, Behrens G M N, Pöhlmann S, Hoffmann M (2021): B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell Reports. 37(2):109825. doi: 10.1016/j.celrep.2021.109825.
     
  26. Arora P, Rocha C, Kempf A, Nehlmeier I, Graichen L, Winkler M S, Lier M, Schulz S, Jäck H-M, Cossmann A, Stankov M, Behrens G M N, Pöhlmann S, Hoffmann M (2021): The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high effificiency. Cellular & Molecular Immunology. 18(12):2673-2675. doi: 10.1038/s41423-021-00779-5.
     
  27. Bdeir N, Arora P, Gärtner S, Pöhlmann S, Winkler M (2021): Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity. Scientific Reports. 11(1):20477. doi: 10.1038/s41598-021-99691-1.
     
  28. Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Arora P, Sidarovich A, Moldenhauer AS, Winkler MS, Schulz S, Jäck HM, Stankov MV, Behrens GMN, Pöhlmann S (2021): SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports. 36(3):109415. doi: 10.1016/j.celrep.2021.109415.
     
  29. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens GMN (2021): Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine. 27(9):1525-1529. doi: 10.1038/s41591-021-01449-9.
     
  30. Hammerschmidt S, Bosnjak B, Bernhardt G, Friedrichsen M, Ravens I, Dopfer-Jablonka A, Hoffmann M, Pöhlmann S, Behrens G M N, Förster R (2021): Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cellular & Molecular Immunology. 18(10):2455-2456. doi: 10.1038/s41423-021-00755-z.
     
  31. Stervbo U, Blazquez-Navarro A, Blanco E, Safi L, Meister T L, Paniskaki K, Stockhausen M, Marheinecke C, Zimmer G, Wellenkötter J, Giglio T, Arora P, Pöhlmann S, Hoffmann M, Seibert F S, Pfaender S, Roch T, Westhoff T H, Cinkilic O, Babel N (2021): Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease. Kidney International. 100(6):1335-1337. doi: 10.1016/j.kint.2021.09.015.
     
  32. Schroeder S, Mache C, Kleine-Weber H, Corman V M, Muth D, Richter A, Fatykhova D, Memish Z A, Stanifer M L, Boulant S, Gultom M, Dijkman R, Eggeling S, Hocke A, Hippenstiel S, Thiel V, Pöhlmann S, Wolff T, Müller M A, Drosten C (2021): Functional comparison of MERS-coronavirus lineages reveals increased replicative fitness of the recombinant lineage 5. Nature Communications. 12(1):5324. doi: 10.1038/s41467-021-25519-1.
     
  33. Behrens G M, Cossmann A, Stankov M V, Nehlmeier I, Kempf A, Hoffmann M, Pöhlmann S (2021): SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet (London, England). 398(10305):1041-1042. doi: 10.1016/S0140-6736(21)01891-2.
     
  34. Hoffmann M, Pöhlmann S (2021): How SARS-CoV-2 makes the cut. Nature Microbiology. 6(7):828-829. doi: 10.1038/s41564-021-00931-x.
     
  35. Tea F, Stella A O, Aggarwal A, Darley D R, Pilli D, Vitale D, Merheb V, Lee F X Z, Cunningham P, Walker G J, Fichter C, Brown D A, Rawlinson W D, Isaacs S R, Mathivanan V, Hoffmann M, Pöhlmann S, Mazigi O, Christ D, Dwyer D E, Rockett R J, Sintchenko V, Hoad V C, Irving D O, Dore G J, Gosbell I B, Kelleher A D, Matthews G V, Brilot F, Turville S G (2021): SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. Plos Medicine. 18(7):e1003656. doi: 10.1371/journal.pmed.1003656.
     
  36. Hempel T, Elez K, Krüger N, Raich L, Shrimp J H, Danov O, Jonigk D, Braun A, Shen M, Hall M D, Pöhlmann S, Hoffmann M, Noé F (2021): Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: Pre-clinical assessment of pharmacological and molecular properties. Chemical Science. 12(38):12600-12609. doi: 10.1039/d1sc01494c.
     
  37. Schuh W, Baus L, Steinmetz T, Schulz SR, Weckwerth L, Roth E, Hauke M, Krause S, Morhart P, Rauh M, Hoffmann M, Vesper N, Reth M, Schneider H, Jäck HM, Mielenz D (2021): A surrogate cell-based SARS-CoV-2 spike blocking assay. European Journal of Immunology. 51(11):2665-2676. doi: 10.1002/eji.202149302.
     
  38. Zech F, Schniertshauer D, Jung C, Herrmann A, Cordsmeier A, Xie Q, Nchioua R, Bozzo C P, Volcic M, Koepke L, Müller J A, Krüger J, Heller S, Stenger S, Hoffmann M, Pöhlmann S, Kleger A, Jacob T, Conzelmann K-K, Ensser A, Sparrer K M J, Kirchhoff F (2021): Nature Communications. 12(1):6855. doi: 10.1038/s41467-021-27180-0.
     
  39. Lapuente D, Fuchs J, Willar J, Antao A V, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter A S, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M (2021): Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications. 12(1):6871. doi: 10.1038/s41467-021-27063-4.
     
  40. Winkler M S, Claus R A, Schilder M, Pöhlmann S, Coldewey S M, Grundmann J, Fricke T, Moerer O, Meissner K, Bauer M, Hofmann-Winkler H, Gräler M H (2021): Erythrocytes increase endogenous sphingosine 1-phosphate levels as an adaptive response to SARS-CoV-2 infection. Clinical Science. 135(24):2781-2791. doi: 10.1042/CS20210666.
     
  41. Abusukhun M, Winkler M S, Pöhlmann S, Moerer O, Meissner K, Tampe B, Hofmann-Winkler H, Bauer M, Gräler M H, Claus R A (2021): Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies. Frontiers in Immunology. 12:784989. doi: 10.3389/fimmu.2021.784989.
     
  42. Geuder J, Wange LE, Janjic A, Radmer J, Janssen P, Bagnoli JW, Müller S, Kaul A, Ohnuki M, Enard W (2021): A non-invasive method to generate induced pluripotent stem cells from primate urine. Scientific Reports. 11(1):3516. doi: 10.1038/s41598-021-82883-0.

 

2020

  1. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020): SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.
     
  2. Hoffmann M, Kleine-Weber H, Pöhlmann S (2020): A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol Cell. 78(4):779-784.e5. doi: 10.1016/j.molcel.2020.04.022.
     
  3. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team, Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS (2020): Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 181(5):1004-1015.e15. doi: 10.1016/j.cell.2020.04.031.
     
  4. Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S (2020): Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 64(6):e00754-20. doi: 10.1128/AAC.00754-20.
     
  5. Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C, Pöhlmann S (2020): Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 585(7826):588-590. doi: 10.1038/s41586-020-2575-3.
     
  6. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, Adams C, Carpinteiro E, Gulbins A, Keitsch S, Sehl C, Soddemann M, Wilker B, Kamler M, Bertsch T, Lang KS, Patel S, Wilson GC, Walter S, Hengel H, Pöhlmann S, Lang PA, Kornhuber J, Becker KA, Ahmad SA, Fassbender K, Gulbins E (2020): Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells. Cell Rep Med. 1(8):100142. doi: 10.1016/j.xcrm.2020.100142.
     
  7. Kleine-Weber H, Schroeder S, Krüger N, Prokscha A, Naim HY, Müller MA, Drosten C, Pöhlmann S, Hoffmann M (2020): Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 9(1):155-168. doi: 10.1080/22221751.2020.1713705.
     
  8. Lambertz RLO, Gerhauser I, Nehlmeier I, Gärtner S, Winkler M, Leist SR, Kollmus H, Pöhlmann S, Schughart K (2020): H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice. Virol J. 17(1):56. doi: 10.1186/s12985-020-01323-z.
     
  9. Edwards MJ, Becker KA, Gripp B, Hoffmann M, Keitsch S, Wilker B, Soddemann M, Gulbins A, Carpinteiro E, Patel SH, Wilson GC, Pöhlmann S, Walter S, Fassbender K, Ahmad SA, Carpinteiro A, Gulbins E (2020): Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. J Biol Chem. 295(45):15174-15182. doi: 10.1074/jbc.RA120.015249.
     
  10. Pfaender S, Mar KB, Michailidis E, Kratzel A, Boys IN, V'kovski P, Fan W, Kelly JN, Hirt D, Ebert N, Stalder H, Kleine-Weber H, Hoffmann M, Hoffmann HH, Saeed M, Dijkman R, Steinmann E, Wight-Carter M, McDougal MB, Hanners NW, Pöhlmann S, Gallagher T, Todt D, Zimmer G, Rice CM, Schoggins JW, Thiel V (2020): LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat Microbiol. 5(11):1330-1339. doi: 10.1038/s41564-020-0769-y.
     
  11. Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, Fricke T, Grundmann J, Harnisch LO, Heise D, Kernchen A, Pressler M, Stephani C, Tampe B, Kaul A, Gärtner S, Kramer S, Pöhlmann S, Winkler MS (2020): Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. Crit Care Explor. 2(11):e0284. doi: 10.1097/CCE.0000000000000284.
     
  12. Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, Roose K, van Schie L; VIB-CMB COVID-19 Response Team, Hoffmann M, Pöhlmann S, Graham BS, Callewaert N, Schepens B, Saelens X, McLellan JS (2020): Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 181(6):1436-1441. doi: 10.1016/j.cell.2020.05.047.
     
  13. Budhadev D, Poole E, Nehlmeier I, Liu Y, Hooper J, Kalverda E, Akshath US, Hondow N, Turnbull WB, Pöhlmann S, Guo Y, Zhou D (2020): Glycan-Gold Nanoparticles as Multifunctional Probes for Multivalent Lectin-Carbohydrate Binding: Implications for Blocking Virus Infection and Nanoparticle Assembly. J Am Chem Soc. 142(42):18022-18034. doi: 10.1021/jacs.0c06793.
     
  14. Behrmann O, Bachmann I, Spiegel M, Schramm M, El Wahed A.A, Dobler G, Dame G, Hufert F.T (2020): Rapid Detection of SARS-CoV-2 by Low Volume Real-Time Single Tube Reverse Transcription Recombinase Polymerase Amplification Using an Exo Probe with an Internally Linked Quencher (Exo-IQ). Chlinical Chemistry. 66(8):1047-1054. doi: 10.1093/clinchem/hvaa116.
     
  15. Hüttl S, Hoffmann M, Steinmetzer T, Sauder C, Krüger N (2020): The Amino Acid at Position 8 of the Proteolytic Cleavage Site of the Mumps Virus Fusion Protein Affects Viral Proteolysis and Fusogenicity. Journal of Virology. 94(22):e01732-20. doi: 10.1128/JVI.01732-20.

2019

  1. Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Müller MA, Drosten C, Pöhlmann S, Hoffmann M (2019): Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization. Journal of Virology. 93(2). pii: e01381-18. doi: 10.1128/JVI.01381-18.
     
  2. Hoffmann M, Nehlmeier I, Brinkmann C, Krähling V, Behner L, Moldenhauer A, Krüger N, Nehls J, Schindler M, Hoenen T, Maisner A, Becker S, Pöhlmann S (2019): Tetherin inhibits Nipah virus but not Ebola virus replication in fruit bat cells. Journal of Virology. 93(3). pii: e01821-18. doi: 10.1128/JVI.01821-18.
     
  3. Hoffmann M, Schütze E, Bernhard A, Schlaphoff L, Kaul A, Schöniger S, Pöhlmann S (2019): Disease manifestation and viral sequences in a bonobo more than 30 years after papillomavirus infection. Pathogens. 8(1). pii: E13. doi: 10.3390/pathogens8010013.
     
  4. Bdeir N, Arora P, Gärtner S, Hoffmann M, Reichl U, Pöhlmann S, Winkler M (2019): A system for production of defective interfering particles in the absence of infectious influenza A virus. Plos One. 14(3):e0212757. doi: 10.1371/journal.pone.0212757.
     
  5. Nehls J, Businger R, Hoffmann M, Brinkmann C, Fehrenbacher B, Schaller M, Maurer B, Schönfeld C, Kramer D, Hailfinger S, Pöhlmann S, Schindler M (2019): Release of Immunomodulatory Ebola Virus Glycoprotein-Containing Microvesicles Is Suppressed by Tetherin in a Species-Specific Manner. Cell Reports. 26(7):1841-1853.e6. doi: 10.1016/j.celrep.2019.01.065.
     
  6. Zapatero-Belinchón FJ, Dietzel E, Dolnik O, Döhner K, Costa R, Hertel B, Veselkova B, Kirui J, Klintworth A, Manns MP, Pöhlmann S, Pietschmann T, Krey T, Ciesek S, Gerold G, Sodeik B, Becker S, von Hahn T (2019): Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. Viruses. 11(3). pii: E275. doi: 10.3390/v11030275.
     
  7. Korniy N, Goyal A, Hoffmann M, Samatova E, Peske F, Pöhlmann S, Rodnina MV (2019): Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance. Nucleic Acids Research. 47(10):5210-5222. doi: 10.1093/nar/gkz202.
     
  8. Plegge T, Spiegel M, Krüger N, Nehlmeier I, Winkler M, González Hernández M, Pöhlmann S (2019): Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins. Plos One. 14(4):e0214968. doi: 10.1371/journal.pone.0214968.
     
  9. Braun E, Hotter D, Koepke L, Zech F, Groß R, Sparrer KMJ, Müller JA, Pfaller CK, Heusinger E, Wombacher R, Sutter K, Dittmer U, Winkler M, Simmons G, Jakobsen MR, Conzelmann KK, Pöhlmann S, Münch J, Fackler OT, Kirchhoff F, Sauter D (2019): Guanylate-Binding Proteins 2 and 5 Exert Broad Antiviral Activity by Inhibiting Furin-Mediated Processing of Viral Envelope Proteins. Cell Reports. 27(7):2092-2104.e10. doi: 10.1016/j.celrep.2019.04.063.
     
  10. Kaul A, Schönmann U, Pöhlmann S (2019): Seroprevalence of viral infections in captive rhesus and cynomolgus macaques. Primate Biology.
     
  11. Winkler M, Wrensch F, Bosch P, Knoth M, Schindler M, Gärtner S, Pöhlmann S (2019): Analysis of IFITM-IFITM interactions by a flow cytometrybased. International Journal of Molecular Sciences. 20(16). pii: E3859. doi: 10.3390/ijms20163859.
     
  12. Voigt K, Hoffmann M, Drexler JF, Müller MA, Drosten C, Herrler G, Krüger N (2019): Fusogenicity of the Ghana Virus (Henipavirus: Ghanaian bat henipavirus) Fusion Protein is Controlled by the Cytoplasmic Domain of the Attachment Glycoprotein. Viruses. 11(9). pii: E800. doi: 10.3390/v11090800.
     
  13. Dhingra A, Ganzenmueller T, Hage E, Suárez NM, Mätz-Rensing K, Widmer D, Pöhlmann S, Davison AJ, Schulz TF, Kaul A (2019): Novel Virus Related to Kaposi's Sarcoma-Associated Herpesvirus from Colobus Monkey. Emerging Infectious Diseases. 25(8):1548-1551. doi: 10.3201/eid2508.181802.
     
  14. Hoffmann M, Kaufmann S, Fischer C, Maurer W, Moldenhauer A, Pöhlmann S (2019): Analysis of resistance of Ebola virus glycoprotein-driven entry against MDL28170, an inhibitor of cysteine cathepsins. Pathogens. 8(4). pii: E192. doi: 10.3390/pathogens8040192.
     
  15. Winkler M, Gärtner S, Markus L, Hoffmann M, Nehlmeier I, Krawczak M, Sauermann U, Pöhlmann S (2019): Role of rhesus macaque IFITM3(2) in simian immunodeficiency virus infection of macaques. Plos One. 14(11):e0224082. doi: 10.1371/journal.pone.0224082.
     
  16. Wrensch F, Ligat G, Heydmann L, Schuster C, Zeisel MB, Pessaux P, Habersetzer F, King BJ, Tarr AW, Ball JK, Winkler M, Pöhlmann S, Keck ZY, Foung SKH, Baumert TF (2019): Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. Hepatology. 70(5):1506-1520. doi: 10.1002/hep.30699.
     
  17. Lambertz RLO, Gerhauser I, Nehlmeier I, Leist SR, Kollmus H, Pöhlmann S, Schughart K (2019): Tmprss2 knock-out mice are resistant to H10 influenza A virus pathogenesis. Journal of General Virology. 100(7):1073-1078. doi: 10.1099/jgv.0.001274.
     
  18. Chukhno E, Gärtner S, Rahman Siregar A, Mehr A, Wende M, Petkov S, Götting J, Dhingra A, Schulz T, Pöhlmann S, Winkler M (2019): A Fosmid-Based System for the Generation of Recombinant Cercopithecine Alphaherpesvirus 2 Encoding Reporter Genes. Viruses. 11(11). pii: E1026. doi: 10.3390/v11111026.
     
  19. Grewer A, Bleyer M, Mätz-Rensing K, Hahn A, Rüggeberg T, Babaryka G, Zimmermann A, Pöhlmann S, Kaul, A (2019): Kaposi Sarcoma in Mantled Guereza. Emerging Infectious Diseases. 25(8):1552-1555. doi: 10.3201/eid2508.181804.
     
  20. Laporte M, Stevaert A, Raeymaekers V, Boogaerts T, Nehlmeier I, Chiu W, Benkheil M, Vanaudenaerde B, Pöhlmann S, Naesens L (2019): Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways. Journal of Virology. 94(1). pii: e01430-19. doi: 10.1128/JVI.01430-19.

 

2018

  1. Maschkowitz G, Gärtner S, Hofmann-Winkler H, Fickenscher H, Winkler M (2018): Interaction of human cytomegalovirus tegument proteins ppUL35 and ppUL35A with Sorting Nexin 5 regulates glycoprotein B (gpUL55) localization. Journal of Virology. 92(9). pii: e00013-18. doi: 10.1128/JVI.00013-18.
     
  2. Hoffmann M, Hofmann-Winkler H, Pöhlmann S (2018): Activation of Viruses by Host Proteases  - Priming Time: How Cellular Proteases Arm Coronavirus Spike Proteins. Springer International Publishing. doi: 10.1007/978-3-319-75474-1.
     
  3. González Hernández M, Hoffmann M, Brinkmann C, Nehls J, Winkler M, Schindler M, Pöhlmann S (2018): A GXXXA motif in the transmembrane domain of the Ebola virus glycoprotein is required for tetherin antagonism. Journal of Virology. 92(13). pii: e00403-18. doi: 10.1128/JVI.00403-18.
     
  4. Hoffmann M, Pöhlmann S (2018): Cell Entry of Influenza A Viruses: Sweet Talk between HA and CaV1.2. Cell Host Microbe. 23(6):697-699. doi: 10.1016/j.chom.2018.05.019.
     
  5. Zmora P, Hoffmann M, Kollmus H, Moldenhauer AS, Danov O, Braun A, Winkler M, Schughart K, Pöhlmann S (2018): TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. Journal of Biological Chemistry. 293(36):13863-13873. doi: 10.1074/jbc.RA118.001273.
     
  6. Kleine-Weber H, Elzayat MT, Hoffmann M, Pöhlmann S (2018): Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Scientific Reports. 8(1):16597. doi: 10.1038/s41598-018-34859-w.
     
  7. Krüger N, Sauder C, Hüttl S, Papies J, Voigt K, Herrler G, Hardes K, Steinmetzer T, Örvell C, Drexler JF, Drosten C, Rubin S, Müller MA, Hoffmann M (2018): Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps Virus. Cell Reports. 25(2):312-320.e7. doi: 10.1016/j.celrep.2018.09.018.

 

2017

  1. Wrensch F, Hoffmann M, Gärtner S, Nehlmeier I, Winkler M, Pöhlmann S (2017): Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins. Journal of Virology. 91(2). pii: e01488-16. doi: 10.1128/JVI.01488-16.
     
  2. Winkler M, Gärtner S, Wrensch F, Krawczak M, Sauermann U, Pöhlmann S (2017): Rhesus macaque IFITM3 gene polymorphisms and SIV infection. PLoS One. 12(3):e0172847. doi: 10.1371/journal.pone.0172847.
     
  3. Hoffmann M, Crone L, Dietzel E, Paijo J, González-Hernández M, Nehlmeier I, Kalinke U, Becker S, Pöhlmann S (2017): A polymorphism within the internal fusion loop of the Ebola virus glycoprotein modulates host cell entry. Journal of Virology. 91(9). pii: e00177-17. doi: 10.1128/JVI.00177-17.
     
  4. Pöhlmann S, Krüger A, Hafezi W, Schneider S, Gruber J, Winkler M, Kaul A (2017): Detection systems for antibody responses against herpes B virus. Primate Biology. doi:10.5194/pb-4-9-2017.
     
  5. Reinke LM, Spiegel M, Plegge T, Hartleib A, Nehlmeier I, Gierer S, Hoffmann M, Hofmann-Winkler H, Winkler M, Pöhlmann S (2017): Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PLoS One. 12(6):e0179177. doi: 10.1371/journal.pone.0179177.
     
  6. Zmora P, Molau-Blazejewska P, Bertram S, Walendy-Gnirß K, Nehlmeier I, Hartleib A, Moldenhauer AS, Konzok S, Dehmel S, Sewald K, Brinkmann C, Curths C, Knauf S, Gruber J, Mätz-Rensing K, Dahlmann F, Braun A, Pöhlmann S (2017): Non-human primate orthologues of TMPRSS2 cleave and activate the influenza virus hemagglutinin. PLoS One. 12(5):e0176597. doi: 10.1371/journal.pone.0176597.
     
  7. Pöhlmann S, Suntz M, Akimkin V, Bleyer M, Kaul A (2017): Herpes B virus replication and viral lesions in the liver of a cynomolgus macaque which died from severe disease with rapid onset. Journal of Medical Primatology. 46(5):256-259. doi: 10.1111/jmp.12269.
     
  8. Gerlach T, Hensen L, Matrosovich T, Bergmann J, Winkler M, Peteranderl C, Klenk HD, Weber F, Herold S, Pöhlmann S, Matrosovich M (2017): pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs. Journal of Virology. 91(11). pii: e00246-17. doi: 10.1128/JVI.00246-17.
     
  9. Hoffmann M, Elzayat MT, Herbig E (2017): Hochpathogene Viren mittels Virus-Pseudotypen erforschen - Der Einfluss von hochreinem Wasser auf die Datenqualität. Laborpraxis.
     
  10. Brinkmann C, Hoffmann M, Lübke A, Nehlmeier I, Krämer-Kühl A, Winkler M, Pöhlmann S (2017): The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells. PLoS One. 12(12):e0189073. doi: 10.1371/journal.pone.0189073.
     
  11. Guo Y, Nehlmeier I, Poole E, Sakonsinsiri C, Hondow N, Brown A, Li Q, Li S, Whitworth J, Li Z, Yu A, Brydson R, Turnbull WB, Pöhlmann S, Zhou D (2017): Dissecting Multivalent Lectin-Carbohydrate Recognition Using Polyvalent Multifunctional Glycan-Quantum Dots. Journal of the American Chemical Society. 139(34):11833-11844. doi: 10.1021/jacs.7b05104.

 

2016

  1. Kühn N, Bergmann S, Kasnitz N, Lambertz RLO, Keppner A, Pöhlmann S, Weiß S, Hummler E, Hatesuer B, Schughart K (2016): The proteolytic activation of A (H3N2) Influenza virus hemagglutinin is facilitated by different type II transmembrane serine proteases. Journal of Virology. 90(9):4298-307.

  2. Hoffmann M, González Hernández M, Berger E, Marzi A, Pöhlmann S (2016): The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent. PLoS One. 11(2):e0149651.

  3. Guo Y, Sakonsinsiri C, Nehlmeier I, Fascione MA, Zhang H, Wang W, Pöhlmann S, Turnbull WB, Zhou D (2016): Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions. Angew Chem Int Ed Engl. 55(15):4738-42.

  4. Hoffmann M, Krüger N, Zmora P, Wrensch F, Herrler G, Pöhlmann S (2016): The Hemagglutinin of Bat-Associated Influenza Viruses Is Activated by TMPRSS2 for pH-Dependent Entry into Bat but Not Human Cells. PLoS One. 11(3):e0152134.

  5. Spiegel M, Plegge T, Pöhlmann S (2016): The Role of Phlebovirus Glycoproteins in Viral Entry, Assembly and Release. Viruses. 8(7).

  6. Plegge T, Hofmann-Winkler H, Spiegel M, Pöhlmann S (2016): Evidence that Processing of the Severe Fever with Thrombocytopenia Syndrome Virus Gn/Gc Polyprotein Is Critical for Viral Infectivity and Requires an Internal Gc Signal Peptide. PLoS One. 11(11):e0166013.

  7. Brinkmann C, Nehlmeier I, Walendy-Gnirß K, Nehls J, González Hernández M, Hoffmann M, Qiu X, Takada A, Schindler M, Pöhlmann S (2016): The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. J Virol. 90(24):11075-11086.

  8. Pöhlmann S, Schmitt C (2016): Orthommyxoviren: Influenza; Arenaviren. Springer Mikrobiologie Lehrbuch.

  9. Pöhlmann S, Spiegel M (2016): Bunyaviren. Springer Mikrobiologie Lehrbuch.

  10. Krüger N, Sauder C, Hoffmann M, Örvell C, Drexler JF, Rubin S, Herrler G (2016): Recombinant mumps viruses expressing the batMuV fusion glycoprotein are highly fusion active and neurovirulent. J Gen Virol. 97(11):2837-2848.

  11. Klippert A, Bleyer M, Sauermann U, Neumann B, Kaul A, Daskalaki M, Stolte-Leeb N, Kirchhoff F, Stahl-Hennig C (2016): Lymphocryptovirus-dependent occurrence of lymphoma in SIV-infected rhesus macaques with particular consideration to two uncommon cases of non-Hodgkin's lymphoma. Primate Biology.

2015

  1. Gierer S, Müller MA, Heurich A, Ritz D, Springstein B, Karsten CB, Schendzielorz A, Gnirß K, Drosten C, Pöhlmann S (2015): Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity. Journal of Infectious Diseases. 211(6): 889-97.

  2. Hofmann-Winkler H, Gnirß K, Wrensch F, Pöhlmann S (2015): Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976. Journal of Infectious Diseases. 212(2): 172-80.

  3. Dahlmann F, Biedenkopf N, Babler A, Jahnen-Dechent W, Karsten CB, Gnirß K, Schneider H, Wrensch F, O'Callaghan CA, Bertram S, Herrler G, Becker S, Pöhlmann S, Hofmann-Winkler H (2015): Analysis of Ebola virus entry into macrophages. Journal of Infectious Diseases. 212(2): 247-57.

  4. Wrensch F, Karsten CB, Gnirß K, Hoffmann M, Lu K, Takada A, Winkler M, Simmons G, Pöhlmann S (2015): Interferon-Induced Transmembrane Protein–Mediated Inhibition of Host Cell Entry of Ebolaviruses. Journal of Infectious Diseases. 212(2): 210-8.

  5. Gnirß K, Zmora P, Blazejewska P, Winkler M, Lins A, Nehlmeier I, Gärtner S, Moldenhauer AS, Hofmann-Winkler H, Wolff T, Schindler M, Pöhlmann S (2015): Tetherin Sensitivity of Influenza A Viruses Is Strain Specific: Role of Hemagglutinin and Neuraminidase. Journal of Virology. 89(18): 9178-88.

  6. Karsten CB, Buettner FF, Cajic S, Nehlmeier I, Neumann B, Klippert A, Sauermann U, Reichl U, Gerardy-Schahn R, Rapp E, Stahl-Hennig C, Pöhlmann S (2015): Exclusive decoration of SIV Env with high-mannose type N-glycans is not compatible with mucosal transmission in rhesus macaques. Journal of Virology. 89(22): 11727-33.

  7. Zmora P, Moldenhauer AS, Hofmann-Winkler H, Pöhlmann S (2015): TMPRSS2 isoform 1 activates respiratory viruses and is expressed in viral target cells. PLoS One. 10(9): e0138380.

  8. Zmora P, Pöhlmann S (2015): New approaches to influenza therapy. Formatex Research Center. 5:1052-1059.

  9. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G (2015): Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research. 116: 76-84.

2014

  1. van Breedam W, Pöhlmann S, Favoreel H W, Groot Raoul J de, Nauwynck H J (2014): Bitter-sweet symphony: glycan-lectin interactions in virus biology. FEMS Microbiology Reviews. 38(4): 598-632.

  2. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F,  Pöhlmann S, Vondran F W R, David S, Manns M P, Ciesek S, Hahn T. von (2014): The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. The Journal of Antimicrobial Chemotherapy. 69(8): 2123-31.

  3. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S (2014): TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike. Journal of Virology. 88(2): 1293-307.

  4. Koppensteiner H, Höhne K, Gondim M V, Gobert F-X, Widder M, Gundlach S, Heigele A, Kirchhoff F, Winkler M, Benaroch P, Schindler M (2014): Lentiviral Nef suppresses iron uptake in a strain specific manner through inhibition of Transferrin endocytosis. Retrovirology. 11:1.

  5. Gnirß K, Fiedler M, Krämer-Kühl A, Bolduan S, Mittler E, Becker S, Schindler M, Pöhlmann S (2014): Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. Viruses. 6(4): 1654-71.

  6. Kiene M, Rethi B, Jansson M, Dillon S, Lee E, Lantto R, Wilson C, Pöhlmann S, Chiodi F (2014): Toll-like receptor 3 signalling up-regulates expression of the HIV co-receptor G-protein coupled receptor 15 on human CD4+ T cells. Plos One. 9(2): e88195.

  7. Eckert N, Wrensch F, Gärtner S, Palanisamy N, Goedecke U, Jäger N, Pöhlmann S, Winkler M (2014): Influenza A Virus Encoding Secreted Gaussia Luciferase as Useful Tool to Analyze Viral Replication and Its Inhibition by Antiviral Compounds and Cellular Proteins. Plos One. 9(5): e97695.

  8. Gierer S, Müller MA, Heurich A, Ritz D, Springstein B, Karsten CB, Schendzielorz A, Gnirß K, Drosten C, Pöhlmann S (2014): Inhibition of proprotein convertases abrogates processing of the MERS-coronavirus spike protein in infected cells but does not reduce viral infectivity. Journal of Infectious Diseases. 211(6): 889-97.

  9. Zmora P, Pöhlmann S (2014): Microscopy as a useful tool to study the proteolytic activation of influenza viruses. Microscopy: advances in scientific research and education. 6:725-731.

  10. Zmora P, Blazejewska P, Moldenhauer A.-S, Welsch K, Nehlmeier I, Wu Q, Schneider H, Pohlmann S, Bertram S (2014): DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry. Journal of Virology. 88(20): 12087-97.

  11. Wrensch F, Winkler M, Pöhlmann S (2014): IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses. 6(9): 3683-98.

  12. Karsten CB, Pöhlmann S (2014): Attachment/Binding. Encyclopedia of AIDS (Springer).

2013

  1. Bertram S, Dijkman R, Habjan M, Heurich A, Gierer S, Glowacka I, Welsch K, Winkler M, Schneider H, Hofmann-Winkler H, Thiel V, Pöhlmann S (2013): TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. Journal of Virology. 87(11): 6150-60.

  2. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittmer U, Hahn T von, Simmons G, Hofmann H, Pöhlmann S (2013): The spike-protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2 and is targeted by neutralizing antibodies. Journal of Virology. 87(10): 5502-11.

  3. Hofmann H, Xingxing L, Zhang X, Liu W, Kühl A, Kaup F, Soldan S, González-Scarano F, Weber F, He Y, Pöhlmann S (2013): The severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as receptor for pH-dependent entry into human and animal cell lines. Journal of Virology. 87(8): 4384-94.

  4. Solomon Tsegaye T, Gnirß K, Rahe-Meyer N, Kiene M, Krämer-Kühl A, Behrens G, Münch J, Pöhlmann S (2013): Platelet activation suppresses HIV-1 infection of T cells. Retrovirology. 10-48.

  5. Simmons G, Pawel Z, Gierer S, Heurich A, Pöhlmann S (2013): Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Research. 100(3): 605-14.

  6. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S (2013): TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the SARS-coronavirus spike-protein. Journal of Virology. 88(2): 1293-307.

  7. Gierer S, Hofmann-Winkler H, Albuali W H, Bertram S, Al-Rubaish, Abdullah A M, Yousef A A, Al-Nafaie A N, Al-Ali A K, Obeid O E, Alkharsah K R, Pöhlmann S (2013): Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia. Emerging Infectious Diseases. 19(12): 2034-6.

  8. Bogdanow B, Weisbach H, Einem J von, Straschewski S, Voigt S, Winkler M, Hagemeier C, Wiebusch L (2013): Human cytomegalovirus tegument protein pp150 acts as a cyclin A2-CDK-dependent sensor of the host cell cycle and differentiation state. Proceedings of the National Academy of Sciences. 110(43): 17510-5.

  9. van Breedam W, Pöhlmann S, Favoreel H W, Groot R J de, Nauwynck H J (2013): Bitter-sweet symphony: glycan-lectin interactions in virus biology. FEMS Microbiology Reviews. 38(4): 598-632.

  10. Hatesuer B, Bertram S, Mehnert N, Bahgat M M, Nelson P S, Pöhlman S, Schughart K, Basler C F (2013): Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice. PLoS Pathogens. 9(12): e1003774.

  11. Lindemann D, Steffen I, Pöhlmann S (2013): Cellular entry of retroviruses. Viral entry into host cells. Springer. 128-149.

2012

  1. Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P, Lucas Jared M, Nelson Peter S, Pöhlmann S, Soilleux Elizabeth J (2012): Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoS One. 7(4): e35876.

  2. Gnirß K, Kühl A, Karsten C, Glowacka I, Bertram S, Kaup F, Hofmann H, Pöhlmann S (2012): Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. Virology. 424(1): 3-10.

  3. Hofmann-Winkler H, Kaup F, Pöhlmann S (2012): Host Cell Factors in Filovirus Entry: Novel Players, New Insights. Viruses. 4(12): 3336-62.

  4. Kiene M, Marzi A, Urbanczyk A, Bertram S, Fisch T, Nehlmeier I, Gnirß K, Karsten C, Palesch D, Münch J, Chiodi F, Pöhlmann S, Steffen I (2012): The role of the alternative coreceptor GPR15 in SIV tropism for human cells. Virology. 433(1): 73-84.

  5. Kühl A, Pöhlmann S (2012): How Ebola Virus Counters the Interferon System. Zoonoses Public Health. 59(2): 116-31.

  6. Müller D, Schreiner S, Schmid M, Groitl P, Winkler M, Dobner T (2012): Functional Cooperation between Human Adenovirus Type 5 Early Region 4, Open Reading Frame 6 Protein, and Cellular Homeobox Protein HoxB7. J Virol. 86(15): 8296-308.

  7. Sinigalia E, Alvisi G, Segré CV, Mercorelli B, Muratore G, Winkler M, Hsiao HH, Urlaub H, Ripalti A, Chiocca S, Palù G, Loregian A, Sticht H (2012): The Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 Is Modified by SUMO in a DNA-Dependent Manner. PLoS One. 7(11): e49630.

  8. Winkler M, Bertram S, Gnirß K, Nehlmeier I, Gawanbacht A, Kirchhoff F, Ehrhardt C, Ludwig S, Kiene M, Moldenhauer A, Goedecke U, Karsten C, Kühl A, Pöhlmann S (2012): Influenza A virus does not encode a tetherin antagonist with Vpu-like activity  and induces IFN-dependent tetherin expression in infected cells. PLoS One. 7(8): e43337.

2011

  1. Pipirou Z, Powlesland AS, Steffen I, Pöhlmann S, Taylor ME, Drickamer K (2011): Mouse LSECtin as a model for a human Ebola virus receptor. Glycobiology. 21(6): 806-12.

  2. Glowacka I, Bertram S, Müller MA, Allen P, Soilleux E, Pfefferle S, Steffen I, Tsegaye TS, He Y, Gnirss K, Niemeyer D, Schneider H, Drosten C, Pöhlmann S (2011): Evidence that TMPRSS2 activates the SARS-coronavirus spike-protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 85(9): 4122-34.

  3. Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, Lu K, Rennekamp AJ, Hofmann H, Bates P, Pöhlmann S (2011): Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology. 413 (2): 265-74.

  4. Kühl A, Hoffmann M, Müller MA, Munster VJ, Gnirß K, Kiene M, Solomon T, Behrens G, Herrler G, Feldmann H, Drosten C, Pöhlmann S (2011): Comparative analysis 1 of Ebola virus glycoprotein interactions with human and bat cells. J. Infect. Dis. 204(3): 840-9.

  5. Kühl A, Banning C,  Marzi A, Votteler J, Steffen I, Bertram S, Glowacka I, Konrad A, Stürzl M, Guo JT, Schubert U, Feldmann H, Behrens G, Schindler M, Pöhlmann S (2011): The Ebola virus glycoprotein and HIV-1 Vpu employ 1 different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204(3): 850-60.

  6. Hofmann H, Pöhlmann S (2011): DC-SIGN: Access Portal for Sweet Viral Killers. Cell Host Microbe. 10(1): 5-7.

  7. Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, Stellberger T, von Dall'armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Züst R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Weßels C, Pöhlmann S, Haas J, Drosten C, von Brunn A (2011): The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors. PLoS Pathog. 7(10): e1002331.

  8. Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, He Y, Simmons G, Drosten C, Soilleux EJ, Jahn O, Steffen I, Pöhlmann S (2011): Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 85(24): 13363-72.

2010

  1. Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Weber F, Eichler J, Drosten C, Pöhlmann S (2010): Differential downregulation of ACE2 by the spike proteins of SARS-coronavirus and human coronavirus NL63. J. Virol. 84(2):1198-205.

  2. Steffen I, Pöhlmann S (2010): Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr. Pharm. Des. 16(9):1143-58.

  3. Kühl A, Münch J, Sauter D, Bertram S, Glowacka I, Steffen I, Specht A, Hofmann H, Schneider H, Behrens G, Pöhlmann S (2010): Calcium-modulating cyclophilin ligand does not restrict retrovirus release. Nat Med. 16(2): 155-6.

  4. Chaipan C, Steffen I, Solomon-Tsegaye T, Bertram S, Glowacka I, Kato Y, Schmökel J, Münch J, Gerardy-Schahn R, Pöhlmann S (2010): Incorporation of podoplanin into human immunodeficiency virus particles mediates binding to the attachment factor CLEC-2 and transmission to target cells. Retrovirology. 7:47.

  5. Bertram S, Glowacka I, Steffen I, Kühl A, Pöhlmann S (2010): Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol. 20(5): 298-310.

  6. Bertram S, Glowacka I, Blazejewska P, Soilleux E, Allen P, Danisch S, Steffen I, Choi SY, Park Y, Schneider H, Schughart K, Pöhlmann S (2010): TMPRSS2 facilitates trypsin-independent influenza virus spread in Caco-2 cells. J. Virol. 84(19): 10016-25.

  7. Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, Pöhlmann S, Simmons G (2010): A Single Asparagine-Linked Glycosylation Site of the SARS-Coronavirus Spike Glycoprotein Facilitates Inhibition by Mannose-Binding Lectin through Multiple Mechanisms. J. Virol. 84 (17): 8753-64.

  8. Solomon-Tsegaye T, Pöhlmann S (2010): The multiple facets of HIV attachment to dendritic cell lectins. Cell Microbiol. 12(11): 1553-61.